Agenus Inc. (NASDAQ:AGEN) Short Interest Down 17.9% in June

Agenus Inc. (NASDAQ:AGEN) saw a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 2,240,000 shares, a decline of 17.9% from the May 31st total of 2,730,000 shares. Approximately 11.2% of the company’s shares are sold short. Based on an average trading volume of 803,700 shares, the days-to-cover ratio is currently 2.8 days.

Analysts Set New Price Targets

AGEN has been the topic of a number of recent analyst reports. StockNews.com assumed coverage on Agenus in a research note on Wednesday, April 17th. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Agenus in a research note on Friday. Finally, B. Riley dropped their price target on Agenus from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, March 18th.

Hedge Funds Weigh In On Agenus

A number of institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. grew its holdings in Agenus by 3,008.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock worth $1,909,000 after buying an additional 2,232,064 shares in the last quarter. Citigroup Inc. grew its holdings in Agenus by 41.0% during the third quarter. Citigroup Inc. now owns 707,213 shares of the biotechnology company’s stock worth $799,000 after buying an additional 205,817 shares in the last quarter. Exchange Traded Concepts LLC grew its holdings in Agenus by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 107,019 shares of the biotechnology company’s stock worth $89,000 after buying an additional 27,137 shares in the last quarter. Caxton Associates LP grew its holdings in Agenus by 247.3% during the third quarter. Caxton Associates LP now owns 390,234 shares of the biotechnology company’s stock worth $441,000 after buying an additional 277,863 shares in the last quarter. Finally, Profund Advisors LLC grew its holdings in Agenus by 8.1% during the third quarter. Profund Advisors LLC now owns 283,404 shares of the biotechnology company’s stock worth $320,000 after buying an additional 21,262 shares in the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Stock Performance

Shares of AGEN opened at $16.75 on Monday. Agenus has a 52-week low of $4.78 and a 52-week high of $38.60. The business’s 50 day moving average price is $13.23 and its two-hundred day moving average price is $12.93. The firm has a market cap of $351.75 million, a PE ratio of -1.30 and a beta of 1.35.

Agenus (NASDAQ:AGEN) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.58) by $0.54. The firm had revenue of $28.01 million for the quarter, compared to analyst estimates of $40.70 million. Research analysts predict that Agenus will post -9.7 EPS for the current fiscal year.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.